Promethean Drug Ideas

Consultants for Innovative Therapeutics Research


Let’s Work Together to Serve Unmet Medical Needs!

Promethean Drug Ideas is a scientific consulting firm with a vision to provide high quality scientific assessments, evaluations and opinions on break-through science and competitive landscape in innovative drug discovery space including unmet medical needs, targets and therapeutic modalities in chronic diseases and precision medicine.

It was founded out of strong passion for Drug Discovery Research & to put to usage experience of over 3 decades in the space with successful track record of discovery of 8 IND enabling small molecule leads, several being first in class.

Why Us?

Promethean Drug
  • The Drug Discovery Research today is at a revolutionary stage exploiting cutting-edge science in hope to serve unmet medical needs.
  • While moving from Innovative target to a full-fledged drug discovery program, maximal strengthening of the innovative scientific hypothesis is integral part of the roadmap to increase likelihood of forward translation of science & to make better decisions on resource commitment and investments.
  • “A priori” scientific evaluations are extremely crucial but at the same time highly science intensive, laborious and need specialized experience and alignment to emerging science and trends in in drug discovery research space.
  • Promethean Drug Ideas extensive expertise in providing scientific assessments, insights, and opinions.
  • We can work as your external “scientific” partner to bring all needed scientific intelligence on your table through intense, 360-degree, deepest dives into ocean of unstructured, complex, constantly evolving science and converting into structured, concise, and meaningful format customized to your niche needs from target to IND lead research road map.
  • Expertise to provide technical consultation to generate various proof-of-concepts (POCs) from in-vitro, ex-vivo, in vivo and translational studies and CRO mapping.

Our Client’s Testimonials

( www.prometheandrugideas.com )
Promethean Drug

Our Forte

Promethean Drug
  • Oriented and constantly updated on emerging trends:
    • Innovative Disease Targets
    • Therapeutic Modalities
    • Newer NCE Design Approaches
    • Break-through Therapeutics
    • Use of AI in Drug Discovery
  • Expertise in multiple therapy areas of Chronic Diseases and Precision Medicine
    • Oncology/Immuno-oncology
    • Inflammation,
    • Autoimmune Diseases
    • Cardiometabolic Diseases
    • Bone Diseases,
    • Neuro-degeneration
    • Rare Diseases
    • Anti-infectives.

Expertise: Scientific Consultations

Promethean Drug

Expertise: Technical Consultations

Promethean Drug

Ready-Available Scientific Deep Dived Reports

Ready to Use” with SWOT analysis, mechanism of action, Preclinical & Clinical rationale

  • Immuno-oncology Small Molecules Targets & Molecule Pipeline
  • Anti-Obesity Small and Large Molecule Targets & Molecules Pipeline

Consultations Across “Target to IND/POM” Value Chain

Promethean Drug

Let’s Work Together to Serve Unmet Medical Needs!

Dr. Neelima Khairatkar Joshi,
President & Founder,
Cell: +91 9819098239

About Drug Discovery Innovation Programme 2024

Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.

This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.

With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.

So, join us in 2024 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.

Companies in attendance for 2024 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.

So, why wait? Register with us to learn more!